Emergent BioSolutions Inc. Cash Flow Statement
EBS / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Emergent BioSolutions Inc. generated $171M in operating cash flow and $157M in free cash flow in FY2025. Free cash flow margin was 21.1% of revenue.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $52.6M | -$190.6M | -$760.5M | -$211.6M | $219.5M | $305.1M | $54.5M | $51.8M | $82.6M | $51.8M | $62.9M | $36.7M | $23.0M | $51.7M | $23.0M |
| Depreciation & Amortization | $95.8M | $108.8M | $125.1M | $143.3M | $123.8M | $50.1M | $49.5M | $28.0M | $32.2M | $28.0M | $23.7M | $22.3M | $9.4M | $6.0M | $9.4M |
| Operating Cash Flow | $170.6M | $58.7M | -$206.3M | -$34.1M | $320.2M | $536.0M | $188.0M | $54.6M | $208.1M | $54.6M | $42.5M | $112.3M | $12.2M | $98.0M | $12.2M |
| Capital Expenditures | $13.8M | $22.9M | $51.6M | $115.8M | $224.1M | $141.0M | $86.9M | $76.2M | $54.8M | $76.2M | $44.8M | $30.7M | $54.0M | $22.1M | $54.0M |
| Free Cash Flow | $156.8M | $35.8M | -$257.9M | -$149.9M | $96.1M | $395.0M | $101.1M | -$21.6M | $153.3M | -$21.6M | -$2.3M | $81.6M | -$41.8M | $75.9M | -$41.8M |
| Share Buybacks | $24.9M | $0 | $0 | $82.1M | $106.0M | $0 | $0 | $0 | $33.1M | $0 | $100.0K | $200.0K | $0 | $0 | $0 |
| FCF Margin | 21.1% | 3.4% | -24.6% | -13.4% | 5.4% | 25.4% | 9.1% | -4.4% | 27.3% | -4.4% | -0.4% | 18.1% | -15.3% | 26.5% | -15.3% |